Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
| Revenue (Most Recent Fiscal Year) | $69.65M |
| Net Income (Most Recent Fiscal Year) | $-81.27M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 23.76 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 7.04 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -153.79% |
| Net Margin (Trailing 12 Months) | -153.84% |
| Return on Equity (Trailing 12 Months) | -46.47% |
| Return on Assets (Trailing 12 Months) | -35.30% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.28 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.08 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 8.89 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.25 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.30 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.91 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.09 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 104.72M |
| Free Float | 100.32M |
| Market Capitalization | $1.66B |
| Average Volume (Last 20 Days) | 2.81M |
| Beta (Past 60 Months) | 2.27 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 61.91% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |